Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD
-0.24 (-2.31%)
At close: Mar 27, 2023, 4:00 PM
+0.20 (1.97%)
After-hours: Mar 27, 2023, 6:51 PM EDT

Total Valuation

Immuneering has a market cap or net worth of $267.80 million. The enterprise value is $167.11 million.

Market Cap 267.80M
Enterprise Value 167.11M

Important Dates

The next earnings date is Tuesday, May 9, 2023, before market open.

Estimated Earnings Date May 9, 2023
Ex-Dividend Date n/a

Share Statistics

Immuneering has 26.44 million shares outstanding. The number of shares has increased by 93.84% in one year.

Shares Outstanding 26.44M
Shares Change (YoY) +93.84%
Shares Change (QoQ) +0.05%
Owned by Insiders (%) 30.53%
Owned by Institutions (%) 44.81%
Float 13.92M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 844.92
Forward PS 477.81
PB Ratio 2.44
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 527.25
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 13.50, with a Debt / Equity ratio of 0.04.

Current Ratio 13.50
Quick Ratio 13.10
Debt / Equity 0.04
Debt / EBITDA n/a
Debt / FCF n/a

Financial Efficiency

Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -97.70%.

Return on Equity (ROE) -39.70%
Return on Assets (ROA) -36.70%
Return on Capital (ROIC) -97.70%
Revenue Per Employee $4,283
Profits Per Employee -$682,616
Employee Count 74
Asset Turnover 0.00
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +30.77% in the last 52 weeks.

Beta (1Y) n/a
52-Week Price Change +30.77%
50-Day Moving Average 5.48
200-Day Moving Average 7.25
Average Volume (30 Days) 43,618

Short Selling Information

The latest short interest is 863,461, so 3.27% of the outstanding shares have been sold short.

Short Interest 863,461
Short Previous Month 829,271
Short % of Shares Out 3.27%
Short % of Float 6.20%
Short Ratio (days to cover) 21.86

Income Statement

In the last 12 months, Immuneering had revenue of $316,952 and -$50.51 million in losses. Loss per share was -$1.91.

Revenue 316,952
Gross Profit 158,830
Operating Income -51.74M
Pretax Income -50.51M
Net Income -50.51M
EBITDA -49.72M
EBIT -50.51M
Loss Per Share -$1.91
Full Income Statement

Balance Sheet

The company has $105.52 million in cash and $4.84 million in debt, giving a net cash position of $100.68 million or $3.81 per share.

Cash & Cash Equivalents 105.52M
Total Debt 4.84M
Net Cash 100.68M
Net Cash Per Share $3.81
Equity / Book Value 109.85M
Book Value Per Share 4.16
Working Capital 100.69M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$44.10 million and capital expenditures -$742,483, giving a free cash flow of -$44.84 million.

Operating Cash Flow -44.10M
Capital Expenditures -742,483
Free Cash Flow -44.84M
FCF Per Share -$1.70
Full Cash Flow Statement


Gross margin is 50.11%, with operating and profit margins of -16,325.77% and -15,937.29%.

Gross Margin 50.11%
Operating Margin -16,325.77%
Pretax Margin -15,937.29%
Profit Margin -15,937.29%
EBITDA Margin -15,685.90%
EBIT Margin -15,937.29%
FCF Margin -14,148.44%

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield -18.86%
FCF Yield -16.75%
Dividend Growth (YoY) n/a
Payout Ratio n/a
Buyback Yield -93.84%
Shareholder Yield -93.84%
Dividend Details

Analyst Forecast

The average price target for Immuneering is $16.32, which is 61.11% higher than the current price. The consensus rating is "Buy".

Price Target $16.32
Price Target Difference 61.11%
Analyst Consensus Buy
Analyst Count 13
Revenue Growth Forecast (5Y) 260.76%
EPS Growth Forecast (5Y) -20.23%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a